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square and Student t- tests for categorical and continuous variables, respectively. 
The effect of the selection of P2Y12 drugs on the time-to-first hospital re-admission 
was determined using a Cox-proportional hazard regression model. We controlled 
for potential confounders whose p-values at the baseline comparison were less 
than 0.1. Results: A total of 9698 patients received PCI with a primary diagnosis 
of ACS, and started prasugrel (n= 7095) or ticagrelor (n= 2603). The ticagrelor treated 
group was older and more likely to have a diagnosis of intracranial hemorrhage, 
cerebrovascular accident, cardiac disorders and renal disorders than the prasugrel 
group. The observed 365-day hazard ratio (HR) of re-admission for ticagrelor was 
1.056 [95% CI: 0.867, 1.285] which was unchanged after controlling for the potential 
confounders (HR: 1.056 [95% CI: 0.867 – 1.286]). ConClusions: The selection of 
third-generation antiplatelet agents following PCI was not associated with a clini-
cally or statistically significant reduction in hospital-readmission.
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Can Data Simulation HelP eValuate Hta outComeS oVer time anD 
FaCilitate early DeCiSion-making? a CaSe StuDy oF tiCagrelor in 
aCute Coronary SynDrome in tHe uk
Dequen P, Cooper NJ, Abrams K
University of Leicester, Leicester, UK
BACkgRound: In October 2011, the National Institute for Health and Care 
Excellence (NICE) recommended the use of ticagrelor in adult patients presenting 
with acute coronary syndrome (ACS) in England and Wales. The relative effective-
ness and cost-effectiveness of ticagrelor compared to clopidogrel—the current 
standard of care in the NHS—were based on results from one large multicentre 
study including over 18,000 ACS patients. Patients were recruited from October 
2006 through to July 2008 and primary trial data analysis, published in September 
2009, demonstrated that ticagrelor significantly reduced the rate of death, myo-
cardial infarction (MI), and/or stroke versus clopidogrel. Delays in completing 
and reporting on RCTs can impede access to new valuable treatments; however, 
data simulation may allow for the continuous modelling of trial results and sup-
port early HTA submissions. oBjeCtives: Using a data simulation approach to 
estimate the relative effectiveness of ticagrelor vs. clopidogrel from recruitment 
to final analysis, we explore whether a trial design with shorter follow-up or the 
publication of an interim analysis could have resulted in a positive NICE decision 
at an earlier time point. Methods: Time-to-event data was extracted from pub-
lished Kaplan-Meir curves and individual patient data was simulated assuming 
censoring and recruitment distributions. The relative effectiveness of ticagrelor 
was assessed as a continuum from 2006 to 2009; and the probability of ticagrelor 
being cost-effective in the UK was also evaluated over time using a trial-based 
economic model. Results: Despite increased uncertainty around the probabili-
ties of death, MI and stroke estimated from immature trial data; results suggest 
that ticagrelor was a cost-effective alternative to clopidogrel before the original 
completed 12 months follow-up. ConClusions: Data simulation allowed us to 
evaluate HTA outcomes prior to the original planned analysis which, in retrospect, 
could have led to an earlier NICE recommendation for ticagrelor in ACS.
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CoSt anD eFFeCtiVeneSS ComPariSon From Beijing meDiCal inSuranCe 
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oBjeCtives: To compare the cost and effectiveness of aspirin and clopidogrel 
in ischemic stroke(IS) patients from data of Beijing medical insurance data-
base. Methods: We randomly selected 10% of patients diagnosed as IS the 
first time during January 2012- December 2012 and then followed their inpatient 
records and prescription records to September 2013 from Beijing urban employees 
and residents medical insurance database. We divided these patients into 5 groups 
according to their drug utilization records during the observation period. Patients 
were divided into 5 groups according to the proportion of aspirin prescription by 
100.0%, 60.1-99.9%, 40.0-60.0%, 0-39.9% and 0(clopidogrel only). We compared the 
rate of recurrences, cost of anti-platelet drugs and rate of hemorrhage events in 
different drug utilization groups. The Kruskal-Wallis test and Bartlett’s test were 
used in the analysis. Results: 4301 patients were identified(age 68.29±13.94, 
male 63.19%), 1477 (34.34%) patients used aspirin only, 1938 (45.06%) patients used 
60-100% aspirin, 465 (10.81%) patients used 40-60% aspirin, 335 (7.78%) patients 
used aspirin 0-40% and 86 (2.01%) patients used clopidogrel only. patients with 
only aspirin recurred less than patients with both aspirin and clopidogrel pre-
scription, patients with 60-100% aspirin prescription recurred less than patients 
with less aspirin prescription. patients with aspirin prescription only spent less 
on anti-platelet drugs than that of patients with both aspirin and clopidogrel 
prescription(p< 0.01),. The rates of hemorrhage events for IS patients of different 
drug groups showed no significant difference(p> 0.05). ConClusions: IS patients 
used more aspirin for anti-platelet treatment. The cost of anti-platelet drugs and 
rate of recurrence of patients who used aspirin only was lower, while no significant 
difference was found in hemorrhage events rates among different drug groups.
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tHromBoemBoliSm (Vte) in PatientS witH aCtiVe CanCer
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oBjeCtives: New oral anticoagulants (NOACs) are available for the treatment and 
prevention of VTE but evidence on their clinical effectiveness compared with existing 
treatments is limited. This research compared the clinical effectiveness of dabigatran, 
rivaroxaban, adjusted standard dose warfarin (warfarin), and low molecular weight 
heparin (LMWH) in people with active cancer following VTE. This research was con-
to apixaban. One-way and probabilistic sensitivity analyses indicated that model 
conclusions were robust over a wide range of inputs. ConClusions: Apixaban 
appears to be a dominant alternative to LMWH/edoxaban for the treatment and 
prevention of VTE.
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oBjeCtives: Uncontrolled hypertension remains a major problem for health care 
systems worldwide, being strictly related to a persistently elevated burden of car-
diovascular morbidity and mortality. Because of the multifactorial nature of hyper-
tension, most patients require combination therapy to achieve blood pressure (BP) 
control. This analysis aimed to further investigate the effectiveness of amlodipine/
valsartan/hydrochlorothiazide (A+V+H) single-pill combination in lowering the BP 
of hypertensive patients, previous assessed in an observational study. Methods: 
This analysis was based on a data registry collected in a prospective, open-
label, observational study conducted in 7132 patients diagnosed with essential 
hypertension and for whom treatment with A+V+H was indicated according to 
clinical practice. The observational period was 3 months. Descriptive analysis, 
hypothesis testing and linear regression models were performed. Results: The 
reduction in systolic blood pressure (RSP) between baseline and last visit was 
23.73±17.51 (mean±SD) while the reduction in diastolic blood pressure (RDP) was 
11.34±10.63 mmHg (mean±SD). A t-test showed that both reductions are statisti-
cally significant (p< < 0.001). Multiple linear regression models were fitted to RSP 
and RDP, to assess the influence of patients’ characteristics, comorbidities and 
previous treatment (R2 = 0.11 and 0.13, respectively). ConClusions: Although 
significant, the model covariates were not sufficient to explain the reduction 
in SP and DP (11% and 13% explained, respectively) found between the base-
line and last visit. Since most of the variables known as relevant to character-
ize hypertension were included in the study, the results allow to conclude that 
reduction found is mainly explained by the treatment with A+V+H single-pill 
combination.
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oBjeCtives: New oral anticoagulants (NOACs) are available for the treatment 
and prevention of VTE, but evidence on their clinical effectiveness compared 
with existing treatments is limited. We compared the clinical effectiveness of 
edoxaban, dabigatran and rivaroxaban using adjusted standard dose warfarin 
(warfarin) as a common comparator in patients with index DVT. This research 
was conducted during a review of the company’s submission (CS) to the National 
Institute for Health and Care Excellence (NICE) Single Technology Appraisal pro-
gramme for the oral direct factor Xa inhibitor, edoxaban. Methods: Randomised 
controlled trials (RCTs) for inclusion were identified using the CS for edoxaban 
(as part of Technology Appraisal [TA] 662). We assessed RCTs for comparability 
based on patient population, disease severity, and treatments received. We con-
ducted a Bayesian MTC and explored fixed and random effects models. Odds ratio 
(OR) was the summary statistic for VTE recurrence and major bleed. Results: 
The network of five RCTs formed a “radiating star”. The Deviance Information 
Criterion (DIC) and the residual deviance with the number of unconstrained 
data points for both outcomes showed fixed and random effects models were 
an equally good fit. Due to the small number of studies and the shape of the 
network, the results from the fixed effects model are presented. Results com-
pared to warfarin were (OR> 1 favours warfarin): VTE recurrence edoxaban OR 0.95 
(95% Credible Interval [95%CrI]: 0.62–1.40), dabigatran OR 1.27 (95%CrI: 0.78–1.97), 
rivaroxaban OR 0.64 (95%CrI: 0.40–0.96); major bleed edoxaban OR 0.84 (95%CrI: 
0.48–1.35), dabigatran OR 0.83 (95%CrI: 0.50–1.31), rivaroxaban OR 0.92 (95%CrI: 
0.37–1.90). ConClusions: Rivaroxaban demonstrated a 36% reduction in risk 
of VTE recurrence compared to warfarin that was statistically significant at the 
5% level. We did not identify other significant differences either when comparing 
NOACs to warfarin or when comparing NOACs with each other.
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oBjeCtives: Randomized controlled trials have provided evidence that both 
prasugrel and ticagrelor can reduce complications in patients with acute coronary 
syndrome (ACS). However, no head-to-head comparisons were performed between 
these third-generation drugs. The aim of this study was to compare the hospital 
admission rates between patients receiving ticagrelor and prasugrel during post 
percutaneous coronary intervention (PCI). Methods: A Retrospective cohort 
study was designed to compare all cause hospitalization over 365 days post PCI 
discharge. Patients who received PCI with an ACS hospitalization between January 
2012 to December 2013 were extracted from the Truven Health Analytics MarketScan 
database. Eligible patients filled either a prasugrel or ticagrelor prescription within 
14 days from the discharge date. To be included in the analytic cohort, patients 
needed to be continuously enrolled in the data over six-months prior to the index 
admission, and comorbid conditions over that period were assessed using Chi-
